XYZAL^® is the active isomer of cetirizine

1. In vitro binding studies revealed that levocetirizine has a 2-fold greater affinity for the human H1 receptor than that of cetirizine
2. The clinical relevance of this finding is unknown

XYZAL^® provides fast and long-lasting relief

In an Environmental Exposure Unit study:^1,2

1. Onset of action was seen at 60 minutes
2. Efficacy was demonstrated at the end of the 24-hour dosing interval

Two-day, placebo-controlled, randomized, double-blind, single-center, parallel-group Environmental Exposure Unit study in 373 patients 16 years of age or older with a documented history of ragweed-induced seasonal allergic rhinitis for at least 2 seasons previous to the study. The study consisted of 3 periods, with pollen exposure starting at 8 am on Day 1 and 8:30 am on Day 2. Period 1 began with drug intake at 10 am and continued until 3 pm. Period 2 ran from 8:30 am the next morning until 10 am. Period 3 began with administration of second dose at 10 am and continued until 2:30 pm. The primary endpoint was the reduction from baseline in the Major Symptom Complex (scale: 0-36; MSC= sum of runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes) over period 1. Secondary endpoints included the onset and duration of action and the reduction in Total Symptom Complex score, nasal obstruction score, and individual symptoms over periods 1, 2, and 3.

XYZAL^® provides once-daily dosing

Once-a-day PM dosing in adults and children:

1. Adult recommended dose: 5 mg per day in patients 12 years of age and older. Some patients may be adequately controlled with 2.5 mg


2. Pediatric recommended dose: 2.5 mg per day for children 6 to 11 years of age. The 2.5 mg should not be exceeded because the systemic exposure with 5mg is approximately twice that of adults. (1/2 teaspoon of oral solution. 1.25 mg should not be exceeded based on comparable exposure to adults receiving 5 mg.)
3. Pediatric recommended dose: 1.25 mg (Oral Solution) per day for children 6 months to 5 years of age. The 1.25 mg should not be exceeded based on comparable exposure to adults receiving 5 mg.
4. A dose adjustment is recommended in patients 12 years of age and older with decreased renal function. Please see full Prescribing Information for dosing adjustments

1. Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004;58:109-118.
2. Data on file, UCB, Inc.